FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters ...

For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

UPF scientists have discovered this 7% of critical areas based on their pioneering analysis model that allows minimizing the ...